Cargando…
Immune responses in the treatment of drug-sensitive pulmonary tuberculosis with phenylbutyrate and vitamin D(3) as host directed therapy
BACKGROUND: We have previously shown that 8 weeks’ treatment with phenylbutyrate (PBA) (500mgx2/day) with or without vitamin D(3) (vitD(3)) (5000 IU/day) as host-directed therapy (HDT) accelerated clinical recovery, sputum culture conversion and increased expression of cathelicidin LL-37 by immune c...
Autores principales: | Rekha, Rokeya Sultana, Mily, Akhirunnesa, Sultana, Tajnin, Haq, Ahsanul, Ahmed, Sultan, Mostafa Kamal, S. M., van Schadewijk, Annemarie, Hiemstra, Pieter S., Gudmundsson, Gudmundur H., Agerberth, Birgitta, Raqib, Rubhana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6033279/ https://www.ncbi.nlm.nih.gov/pubmed/29973153 http://dx.doi.org/10.1186/s12879-018-3203-9 |
Ejemplares similares
-
Oral intake of phenylbutyrate with or without vitamin D(3) upregulates the cathelicidin LL-37 in human macrophages: a dose finding study for treatment of tuberculosis
por: Mily, Akhirunnesa, et al.
Publicado: (2013) -
Significant Effects of Oral Phenylbutyrate and Vitamin D3 Adjunctive Therapy in Pulmonary Tuberculosis: A Randomized Controlled Trial
por: Mily, Akhirunnesa, et al.
Publicado: (2015) -
Phenylbutyrate Counteracts Shigella Mediated Downregulation of Cathelicidin in Rabbit Lung and Intestinal Epithelia: A Potential Therapeutic Strategy
por: Sarker, Protim, et al.
Publicado: (2011) -
Host Directed Therapy Against Infection by Boosting Innate Immunity
por: Bergman, Peter, et al.
Publicado: (2020) -
Host-Directed Therapy as a Novel Treatment Strategy to Overcome Tuberculosis: Targeting Immune Modulation
por: Ahmed, Sultan, et al.
Publicado: (2020)